Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.

Shah M, Dowdy D, Joloba M, Ssengooba W, Manabe YC, Ellner J, Dorman SE.

AIDS. 2013 Nov 28;27(18):2883-92. doi: 10.1097/QAD.0000000000000008.

2.

Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals.

Shah M, Ssengooba W, Armstrong D, Nakiyingi L, Holshouser M, Ellner JJ, Joloba M, Manabe YC, Dorman SE.

AIDS. 2014 Jun 1;28(9):1307-14. doi: 10.1097/QAD.0000000000000264.

3.

Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.

Tesfaye A, Fiseha D, Assefa D, Klinkenberg E, Balanco S, Langley I.

BMC Infect Dis. 2017 May 2;17(1):318. doi: 10.1186/s12879-017-2417-6.

4.

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults.

Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, Steingart KR.

Cochrane Database Syst Rev. 2016 May 10;(5):CD011420. doi: 10.1002/14651858.CD011420.pub2. Review.

5.

Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.

Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, Davis JL, Whitelaw A, Nicol MP, Gler MT, Khaliqov A, Zamudio C, Perkins MD, Boehme CC, Cobelens F.

PLoS Med. 2011 Nov;8(11):e1001120. doi: 10.1371/journal.pmed.1001120. Epub 2011 Nov 8.

6.

Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing.

Peter J, Theron G, Chanda D, Clowes P, Rachow A, Lesosky M, Hoelscher M, Mwaba P, Pym A, Dheda K; TB-NEAT team.

BMC Infect Dis. 2015 Jul 9;15:262. doi: 10.1186/s12879-015-0967-z.

7.

Microscopic observation drug-susceptibility assay vs. Xpert® MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis.

Wikman-Jorgensen PE, Llenas-García J, Pérez-Porcuna TM, Hobbins M, Ehmer J, Mussa MA, Ascaso C.

Trop Med Int Health. 2017 Jun;22(6):734-743. doi: 10.1111/tmi.12879. Epub 2017 May 2.

PMID:
28380276
8.

Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study.

Lawn SD, Kerkhoff AD, Vogt M, Wood R.

Lancet Infect Dis. 2012 Mar;12(3):201-9. doi: 10.1016/S1473-3099(11)70251-1. Epub 2011 Oct 17.

9.

Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.

Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA.

PLoS Med. 2012;9(11):e1001347. doi: 10.1371/journal.pmed.1001347. Epub 2012 Nov 20.

10.

Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort.

Lawn SD, Kerkhoff AD, Burton R, Schutz C, Boulle A, Vogt M, Gupta-Wright A, Nicol MP, Meintjes G.

BMC Med. 2017 Mar 21;15(1):67. doi: 10.1186/s12916-017-0822-8.

11.

Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.

Choi HW, Miele K, Dowdy D, Shah M.

Int J Tuberc Lung Dis. 2013 Oct;17(10):1328-35. doi: 10.5588/ijtld.13.0095.

12.

The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.

Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, Horsburgh CR, Losina E, Freedberg KA, Walensky RP.

AIDS. 2012 May 15;26(8):987-95. doi: 10.1097/QAD.0b013e3283522d47.

13.

Outcomes of a clinical diagnostic algorithm for management of ambulatory smear and Xpert MTB/Rif negative HIV infected patients with presumptive pulmonary TB in Uganda: a prospective study.

Walusimbi S, Semitala F, Bwanga F, Haile M, De Costa A, Davis L, Joloba M, Hoffner S, Kamya M.

Pan Afr Med J. 2016 Mar 31;23:154. doi: 10.11604/pamj.2016.23.154.7995. eCollection 2016.

14.

Incremental Yield of Including Determine-TB LAM Assay in Diagnostic Algorithms for Hospitalized and Ambulatory HIV-Positive Patients in Kenya.

Huerga H, Ferlazzo G, Bevilacqua P, Kirubi B, Ardizzoni E, Wanjala S, Sitienei J, Bonnet M.

PLoS One. 2017 Jan 26;12(1):e0170976. doi: 10.1371/journal.pone.0170976. eCollection 2017.

15.

Implementation and Operational Research: What Happens After a Negative Test for Tuberculosis? Evaluating Adherence to TB Diagnostic Algorithms in South African Primary Health Clinics.

McCarthy KM, Grant AD, Chihota V, Ginindza S, Mvusi L, Churchyard GJ, Fielding KL.

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):e119-26. doi: 10.1097/QAI.0000000000000907.

16.

Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru.

Shah L, Rojas M, Mori O, Zamudio C, Kaufman JS, Otero L, Gotuzzo E, Seas C, Brewer TF.

Epidemiol Infect. 2017 Apr;145(6):1107-1117. doi: 10.1017/S0950268816003186. Epub 2017 Feb 6.

PMID:
28162099
17.

Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture.

Balcha TT, Sturegård E, Winqvist N, Skogmar S, Reepalu A, Jemal ZH, Tibesso G, Schön T, Björkman P.

PLoS One. 2014 Jan 22;9(1):e85478. doi: 10.1371/journal.pone.0085478. eCollection 2014.

18.

Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design.

Naidoo P, Dunbar R, Lombard C, du Toit E, Caldwell J, Detjen A, Squire SB, Enarson DA, Beyers N.

PLoS One. 2016 Mar 1;11(3):e0150487. doi: 10.1371/journal.pone.0150487. eCollection 2016.

19.

The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce.

Peter JG, Theron G, Muchinga TE, Govender U, Dheda K.

PLoS One. 2012;7(7):e39966. doi: 10.1371/journal.pone.0039966. Epub 2012 Jul 9.

20.

Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy.

Abimbola TO, Marston BJ, Date AA, Blandford JM, Sangrujee N, Wiktor SZ.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):e1-7. doi: 10.1097/QAI.0b013e318246538f.

PMID:
22240465

Supplemental Content

Support Center